Key Highlights

  • Shares rose 1.67% in today's session to around $260.76 ahead of next week's quarterly Earnings report.
  • Two-year data showed at least 72% of patients achieved a 90% improvement in skin clearance through week 112.
  • At least 46% of patients achieved completely clear skin, sustained from week 64 through week 112.
  • Among responders who stopped treatment and later restarted, 85% regained their prior response within 24 weeks.

Two-Year Data Reinforces a Differentiated Oral Option

Johnson & Johnson (NYSE:JNJ) shares climbed in today's session after the company presented new two-year results from its Phase 3 ICONIC-LEAD study of Icotyde, a targeted oral peptide treatment for moderate to severe plaque psoriasis. The data was presented at the Fall Clinical Dermatology Conference 2026.

Icotyde works differently from many existing psoriasis treatments by directly blocking a receptor involved in the inflammatory response, delivered as a once-daily pill rather than an injection.

High, Sustained Response Rates Through Week 112

At least 72% of patients achieved a 90% improvement in their psoriasis severity score, and at least 46% achieved completely clear skin, with both response rates sustained from week 64 through week 112. Itch improvement was also sustained in 78% of patients across the same period.

Among patients who had responded well and were later withdrawn from treatment, 85% regained their prior response within 24 weeks of restarting, suggesting the drug's effect can be recaptured quickly if treatment is paused and resumed.

A Diversified Healthcare Giant Ahead of Earnings

Johnson & Johnson carries a market Capitalization above $628 billion, spanning innovative medicine and medical technology segments. Shares have been recovering steadily ahead of third-quarter earnings due later this month, with the stock also drawing recent price target increases from several research firms.

Outlook: Durability Data Could Support Broader Adoption

With no new safety signals identified through two years of data, investors are likely to watch how Icotyde's long-term consistency translates into prescribing trends as the drug competes against injectable alternatives. The company's upcoming earnings report will also offer a broader read on performance across its wider healthcare portfolio.